FDA ApprovedUnited States
New Radiation Treatment for Hormone-Sensitive Metastatic Prostate Cancer
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) — targeted radiation given with hormone-pathway pills for metastatic prostate cancer that still responds to hormone therapy
FDA approval on 31 July 2026 for a new use of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) injection — a radioligand given by IV — in combination with…
This is for adults with metastatic prostate cancer that still responds to hormone-pathway therapy, whose tumors light up on a PSMA PET scan, and who may be…